Literature DB >> 1858156

Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use.

T C Noordzij1, K M Leunissen, J P Van Hooff.   

Abstract

The incidence of gouty arthritis and the role of renal urate handling and diuretic use were studied in 85 cadaveric kidney graft recipients with a graft functioning for at least two years. The incidence of gout was 24% in patients using cyclosporine (CsA, n = 55); no patient using azathioprine (Aza, n = 23) had gout. In patients using CsA, the fractional urate clearance decreased between 1 and 3 months after transplantation, thereafter remaining stable at a significantly lower level than in patients using Aza, pointing toward a specific effect of CsA on tubular urate handling. This impaired fractional urate clearance was not reversible up to 18 months in 7 patients after conversion from CsA to Aza, suggesting irreversible tubular damage. Multiregression analysis showed that the impaired fractional urate clearance and the use of furosemide were significant contributors to the occurrence of gout in patients using CsA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1858156     DOI: 10.1097/00007890-199107000-00013

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Hyperuricemia and gout following pediatric renal transplantation.

Authors:  Giuseppina Spartà; Markus J Kemper; Thomas J Neuhaus
Journal:  Pediatr Nephrol       Date:  2006-09-01       Impact factor: 3.714

Review 2.  Gout in solid organ transplantation: a challenging clinical problem.

Authors:  Lisa Stamp; Martin Searle; John O'Donnell; Peter Chapman
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Percutaneous nephrolithotomy in renal transplants: a safe approach with a high stone-free rate.

Authors:  Mário Oliveira; Frederico Branco; Lasalete Martins; Estevao Lima
Journal:  Int Urol Nephrol       Date:  2010-09-17       Impact factor: 2.370

4.  New-Onset Gout as an Independent Risk Factor for Returning to Dialysis After Kidney Transplantation.

Authors:  Justin W Li; David Yin; Zheng Wang; Mark D Brigham; Brian D LaMoreaux; Jeffrey D Kent; Megan Francis-Sedlak; Richard J Johnson; Nandini Hadker; Kevin M Francis; Herman A Sanchez; Gavin Miyasato
Journal:  Transplant Direct       Date:  2020-11-16

Review 5.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

6.  Natural history and etiology of hyperuricemia following pediatric renal transplantation.

Authors:  V O Edvardsson; B A Kaiser; M S Polinsky; J A Palmer; R Quien; H J Baluarte
Journal:  Pediatr Nephrol       Date:  1995-02       Impact factor: 3.714

7.  New and improved strategies for the treatment of gout.

Authors:  Natalie Dubchak; Gerald F Falasca
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-11-24

8.  Tophaceous gout in a renal allograft recipient.

Authors:  Sung-Hua Chuang; Zi-Hong You; Wu-Chang Yang; Tung-Po Huang; Chih-Ching Lin
Journal:  NDT Plus       Date:  2010-02-28

9.  Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout.

Authors:  Rachel Murdoch; Michael J Barry; Hyon K Choi; Daniel Hernandez; Brianne Johnsen; Manuel Labrador; Susan Reid; Jasvinder A Singh; Robert Terkeltaub; Janitzia Vázquez Mellado; Nicola Dalbeth
Journal:  RMD Open       Date:  2021-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.